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Abstract: Genome-wide association studies have revealed a locus at 8p12 that is associated with breast
cancer risk. Fine-mapping of this locus identified 16 candidate causal variants (CCVs). However,
as these variants are intergenic, their function is unclear. To map chromatin looping from this risk
locus to a previously identified candidate target gene, DUSP4, we performed chromatin conformation
capture analyses in normal and tumoural breast cell lines. We identified putative regulatory elements,
containing CCVs, which looped to the DUSP4 promoter region. Using reporter gene assays, we found
that the risk allele of CCV rs7461885 reduced the activity of a DUSP4 enhancer element, consistent
with the function of DUSP4 as a tumour suppressor gene. Furthermore, the risk allele of CCV
rs12155535, located in another DUSP4 enhancer element, was negatively correlated with looping of
this element to the DUSP4 promoter region, suggesting that this allele would be associated with
reduced expression. These findings provide the first evidence that CCV risk alleles downregulate
DUSP4 expression, suggesting that this gene is a regulatory target of the 8p12 breast cancer risk locus.
Keywords: breast cancer risk; GWAS; candidate causal variant; chromatin conformation capture;
reporter gene activity; enhancer; promoter
1. Introduction
Genome-wide association studies by the Breast Cancer Association Consortium (BCAC) and
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) have previously found genetic variants
at 8p12 associated with breast cancer risk [1–4]. In the largest study, the most significant association
was for the rarer allele (A) of single nucleotide polymorphism rs9693444 with a per-allele odds ratio
(OR) = 1.06 (95% CI 1.04–1.08; p = 2 × 10−21) [1]. Subsequent fine-mapping analysis of BCAC and
CIMBA data at this locus revealed 16 candidate causal variants (CCVs; Supplementary Table S1),
including rs9693444, which could not be statistically separated from each other using a likelihood
ratio criterion of 100:1 [5]. The CCVs are located in an intergenic region ≥300 kb centromerically from
DUSP4 and ≥285 kb telomerically from the microRNA MIR3148.
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A major obstacle in the follow-up of genome-wide association study (GWAS) loci is the
identification of target genes. Indeed, given the intergenic location of the CCVs at 8p12, it is
unclear what function the risk variation may have. To identify breast cancer GWAS target genes, we
previously developed a pipeline called INQUISIT (integrated expression quantitative trait and in silico
prediction of GWAS targets). INQUISIT incorporates functional genomic data from breast cell lines
and tissues, providing a score to prioritise identified target genes [3,5]. In our latest fine-mapping
study, INQUISIT revealed seven target genes at the 8p12 breast cancer risk locus, of which only DUSP4
was a high confidence target [5]. This prediction was partly based on evidence of long-range regulatory
chromatin interactions between CCVs and the DUSP4, promoter which included RNA polymerase
II chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) data in a breast cancer
cell line [6], Hi-C chromatin-interaction and bioinformatic analysis identifying an enhancer coincident
with CCVs that interacts with the DUSP4 promoter [7], and capture Hi-C data from breast cancer cell
lines [8].
The chromatin interaction data identified through INQUISIT suggest that CCVs could regulate
DUSP4 expression through enhancer–promoter interactions. This may be a common mechanism
through which GWAS variants act (reviewed in [9]). Indeed, at a number of breast cancer GWAS risk
loci, we have previously shown that CCVs in regulatory elements loop to promoters and regulate their
activity [3,10,11]. In the current study, we mapped long-range chromatin interactions between the
8p12 risk locus and the promoter region of DUSP4. We provide evidence that a CCV, coincident with a
putative regulatory element (PRE) that interacts with DUSP4, can regulate DUSP4 promoter activity.
Furthermore, we found a CCV in a different PRE that was associated with allele-specific chromatin
looping to the DUSP4 promoter region. These data suggest strongly that DUSP4 is a target gene of
breast cancer risk variation at the 8p12 locus.
2. Results
2.1. Chromatin Conformation Capture (3C) Analyses Confirmed That the 8p12 Risk Locus Physically Interacted
with the Promoter Region of DUSP4
To map chromatin interactions between specific regions of the 8p12 risk locus (defined by EcoRI
restriction fragments; Figure 1) and the DUSP4 promoter in breast cells, chromatin conformation
capture (3C) analyses were conducted in breast cancer (MCF-7 and T-47D) and normal mammary
epithelial (Bre-80) cell lines. Some level of interaction with the DUSP4 promoter was observed in all
three cell lines across the 3C restriction fragments at the risk locus (Figure 1). Notably, this broad level
of activity is not often observed in 3C analyses. For example, the 2q35 and 5q11.2 breast cancer risk
loci are considerably closer (≤100 kb) to corresponding promoter targets than 8p12 CCVs are to the
DUSP4 promoter region, yet many restriction fragments at these loci have no observable promoter
interaction [10,11]. At the 8p12 locus, three 3C restriction fragments (#10, #11 and #12) with Hi-C and/or
ChIA-PET evidence of chromatin looping to the DUSP4 promoter demonstrated peaks of interaction in
the breast cell lines (Figure 1), highlighting two fragments (#11 and #12) which contain CCVs (two and
three, respectively) for further analysis.
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Figure 1. Candidate risk variants (CCVs) were located in putative regulatory elements (PREs) that 
interact with the DUSP4 promoter. The figure shows the 8p12 breast cancer risk locus annotated with 
breast cell functional genomic data and 3C analyses of interactions between EcoRI fragments and the 
DUSP4 promoter region (located ≥300 kb upstream) in Bre-80, MCF-7, and T-47D cells. Functional 
genomic data from normal mammary epithelial cells (HMEC and MCF-10A) and breast cancer cell 
lines (MCF-7 and T-47D) in this figure include Hi-C analysis [7] and ENCODE data accessed from the 
Univeristy of California Santa Cruz Genome Browser: RNA polymerase II chromatin interaction 
analysis by paired-end tag sequencing (ChIA-PET), epigenetic marks characteristic of enhancers 
(DNaseI hypersensitivity sites and H3K4Me1, H3K4Me2, and H3K27Ac histone modifications), and 
transcription factor binding (Pol2, STAT3, MYC, and FOS). Notably, all ChIA-PET anchors and the 
predicted Hi-C enhancer looped to the DUSP4 promoter. For the 3C analyses, interaction frequencies 
were normalised to those of fragment 8, a common peak of interaction in all three cell lines. Interaction 
frequencies from three independent biological replicates are shown (error bars represent standard 
error of the mean). Fragments demonstrating interaction peaks and encompassing PREs with CCVs 
are bounded by boxes. The PRE regions cloned for reporter gene analysis are highlighted in pink. 
2.2. CCV rs7461885 Reduced the Enhancer Activity of PRE1 on the DUSP4 Promoter 
From analysis of the 3C, ChIA-PET, and epigenetic data at the 8p12 locus (Figure 1), CCVs in 
two putative regulatory elements (PRE1-2) were prioritized for reporter gene analyses to determine 
their effects on DUSP4 promoter activity (Figure 2). PRE1, containing three CCVs, significantly 
enhanced DUSP4 promoter activity by 2.3- and 2.5-fold in Bre-80 and MCF-7 cells, respectively 
(Figure 2a,b). In these two cell lines, the risk-associated allele of rs7461885, whether as a single variant 
or in a haplotype with the risk alleles of two other CCVs, significantly reduced the PRE1 enhancer 
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lines ( CF-7 and T-47D) in this figure include Hi-C analysis [7] and ENCODE data accessed from
the Univeristy of California Santa Cruz Genome Browser: RNA polymerase II chromatin interaction
analysis by paired-end tag sequencing (ChIA-PET), epigenetic marks characteristic of enhancers
(DNaseI hypersensitivity sites and H3K4Me1, H3K4Me2, and H3K27Ac histone modifications), and
transcription factor binding (Pol2, STAT3, MYC, and FOS). Notably, all ChIA-PET anchors and the
predicted Hi-C enhancer looped to the DUSP4 promoter. For the 3C analyses, interaction frequencies
were normalised to those of fragment 8, a common peak of interaction in all three cell lines. Interaction
frequencies from three independent biological replicates are shown (error bars represent standard error
of the mean). Fragments demonstrating interaction peaks and encompassing PREs with CCVs are
bounded by boxes. The PRE regions cloned for reporter gene analysis are highlighted in pink.
2.2. CCV rs7461885 Reduced the Enhancer Activity of PRE1 on the DUSP4 Promoter
From analysis of the 3C, ChIA-PET, and epigenetic data at the 8p12 locus (Figure 1), CCVs in two
putative regulatory elements (PRE1-2) were prioritized for reporter gene analyses to determine their
effects on DUSP4 promoter activity (Figure 2). PRE1, containing three CCVs, significantly enhanced
DUSP4 promoter activity by 2.3- and 2.5-fold in Bre-80 and MCF-7 cells, respectively (Figure 2a,b).
In these two cell lines, the risk-associated allele of rs7461885, whether as a single variant or in a
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haplotype with the risk alleles of two other CCVs, significantly reduced the PRE1 enhancer activity by
1.3–1.5 fold (Figure 2a,b). Analysis of rs7461885 using HaploReg [12] did not indicate any evidence
for transcription factor motifs or binding; however, this variant is located in active histone marks
(H3K4Me1, H3K4Me2, and H3K27Ac) in normal mammary epithelial cells (Figure 1). PRE2, containing
two CCVs, significantly enhanced DUSP4 promoter activity by 2.5- and 2.7-fold in MCF-7 and Bre-80
cells, respectively, but neither CCV affected this enhancer activity, nor did the haplotype containing
both risk alleles (Figure 2c,d). Reporter assays were also performed in T-47D cells, but neither PREs
nor CCVs significantly affected DUSP4 promoter activity (Supplementary Figure S1).
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activity in Bre-80 cells, and (d) PRE2 activity in MCF-7 cells. Error bars denote 95% confidence 
intervals of experiments performed in triplicate. p-values were determined two-way ANOVA 
followed by Dunnett’s multiple comparisons test (*p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001). 
2.3. CCV rs12155535 (PRE2) Was Associated with Allele-Specific Looping to the DUSP4 Promoter Region 
Of the three breast cell lines used in the 3C assay, only one (Bre-80) was heterozygous for CCVs 
and thus amenable for allele-specific 3C analysis. After assessing CCVs in the PREs and their 
proximity to the 3C restriction sites, we found that only PRE2 could be analysed for allele-specific 
looping using PCR-based Sanger sequencing. Using Bre-80 3C libraries, we found that there was a 
reduction of the risk (C) allele of CCV rs12155535 in PRE2 interactions, compared to the Bre-80 
genomic DNA control (Figure 3). This finding indicates that the risk allele was negatively correlated 
with the PRE2 enhancer-DUSP4 promoter region interaction, suggesting that risk allele may be 
associated with diminished DUSP4 expression through a reduction in enhancer looping to the DUSP4 
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Figure 2. PREs enhanced DUSP4 promoter activity in luciferase reporter assays and the risk allele
of CCV rs7461885 reduced putative regulatory element 1 (PRE1) enhancer activity. PRE1 and PRE2
reference regions, containing protective allelic variants of CCVs, were cloned downstream of a DUSP4
promoter luciferase construct for the creation of reference (ref) constructs. Risk allelic variants of
CCVs were engineered into the constructs and were designated by the rs ID of the corresponding
variant. Constructs containing risk allele haplotypes (hap) were also generated. Cells were transiently
transfected with each of these constructs and assayed for luciferase activity after 24 h. Panels show
back-transformed data for (a) PRE1 activity in Bre-80 cells, (b) PRE1 activity in MCF-7 cells, (c) PRE2
activity in Bre-80 cells, and (d) PRE2 activity in MCF-7 cells. Error bars denote 95% confidence intervals
of experiments performed in triplicate. p-values were determined two-way ANOVA followed by
Dunnett’s multiple comparisons test (* p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001).
2.3. CCV rs12155535 (PRE2) Was Associated with Allele-Specific Looping to the DUSP4 Promoter Region
Of the three breast cell lines used in the 3C assay, only one (Bre-80) was heterozygous for CCVs
and thus amenable for allele-specific 3C analysis. After assessing CCVs in the PREs and their proximity
to the 3C restriction sites, we found that only PRE2 could be naly ed for allele-specific looping using
PCR-based Sanger sequencing. Using Bre-80 3C libraries, we foun that there was a reduction of
the r sk (C) allele of CCV rs12155535 in PRE2 interactions, compared to the Bre-80 genomic DNA
control (Figure 3). This finding indicates that the risk allele was n g tively correlated with the PRE2
enhancer- USP4 p moter gion interaction, suggesting that ri a lele may be associated with
diminished DUSP4 expr ssion through a reduction in enhan er loopin to the DUSP4 promoter region.
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are located in areas of active chromatin, as indicated by the presence of transcription factor binding 
and strong histone peaks characteristic of enhancers (Figure 1). CCVs in PRE1 and PRE2 were tested 
for effects on the DUSP4 promoter, and the risk allele of CCV rs7461885 was found to repress the 
DUSP4 enhancer activity of PRE1. It is possible that other CCVs at the 8p12 locus, which were not 
assessed in the reporter gene assays, may also regulate DUSP4; however, the available epigenetic 
data suggested these variants were less likely to be functional. 
Finally, we performed an allele-specific 3C analysis and found that the risk allele of CCV 
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Figure 3. Allele-specific interaction between PRE2 and the DUSP4 promoter region. Bre-80 cells
are heterozygous for the rs12155535 CCV in PRE2. Allele-specific analysis using PCR-based Sanger
sequencing of two independent 3C libraries indicated that sequence containing the protective (T) allele
of rs12155535 preferentially interacted with the DUSP4 promoter region.
3. Discussion
In this study, we used genetic approaches to identify functional CCVs and regulatory targets at
the 8p12 breast cancer risk locus. Firstly, we performed 3C in normal and breast cancer cell lines to map
chromatin interactions between PREs, containing CCVs, and the DUSP4 promoter region. Although
we cannot rule out interactions with other genes at this locus, these findings were consistent with
available chromatin interaction analyses, and no other high-confidence targets were predicted by the
INQUISIT pipeline in this region [5].
Secondly, we prioritised two PREs with evidence of interaction with the DUSP4 promoter region
(i.e., PRE1-2) for reporter gene analyses. These assays demonstrated that PRE1 and PRE2 acted as
enhancers of DUSP4 promoter activity in both normal and tumoural breast cell lines. PRE1 and PRE2
are located in areas of active chromatin, as indicated by the presence of transcription factor binding and
strong histone peaks characteristic of enhancers (Figure 1). CCVs in PRE1 and PRE2 were tested for
effects on the DUSP4 promoter, and the risk allele of CCV rs7461885 was found to repress the DUSP4
enhancer activity of PRE1. It is possible that other CCVs at the 8p12 locus, which were not assessed in
the reporter gene assays, may also regulate DUSP4; however, the available epigenetic data suggested
these variants were less likely to be functional.
Finally, we performed an allele-specific 3C analysis and found that the risk allele of CCV
rs12155535 was present less often in PRE2-DUSP4 promoter region interactions in comparison with the
protective allele. As the reporter gene assays had demonstrated that PRE2 acted as a DUSP4 enhancer,
the association of the rs12155535 risk allele with reduced PRE2-DUSP4 interaction frequency was
consistent with the negative effect of the risk allele of rs7461885 on DUSP4 promoter activity.
The 3C and reporter gene findings indicate that DUSP4 is a likely target gene and is downregulated
by risk associated variation at the 8p12 locus. A limitation of the reporter gene analysis is that because
it is plasmid-based it does not model long-range interaction regulatory effects that occur in the human
genome. Nonetheless, enhancers are understood to maintain their functions in reporter plasmids,
despite the artificial genetic environment, and reporter assays are considered the “gold standard”
for assessing enhancer activity [13]. Indeed, data suggest that distance is not essential for regulatory
interaction in a plasmid-based assay—Tewhey et al. estimated a positive predictive value of up to 68%
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when validating expression quantitative trait loci (eQTLs) using reporter plasmids that incorporate
only 150 bp of enhancer sequence and a minimal promoter [14].
Expression quantitative trait loci data from mammary tissue (n = 396) in the Genotype Tissue
Expression database (version 8; https://gtexportal.org/home/ accessed on 9 October 2019) and tumour
tissue (n = 799) in The Cancer Genome Atlas eQTL browser (https://albertlab.shinyapps.io/tcga_eqtl/
accessed on 9 October 2019) provided no evidence that CCVs are associated with DUSP4 expression
in normal or tumour breast tissue. A lack of CCV eQTLs at cancer risk GWAS loci is a common
finding [10,11,15,16] and could be due to several issues: (i) the available eQTL studies may not have
enough statistical power to detect modest effects (as observed in the reporter gene assay) on DUSP4
expression, for example, eQTLs were found at a third of breast cancer GWAS risk loci only after
combining data from four relevant eQTL studies (n = 2820) [17]; (ii) the tissues used, especially tumour
tissue, were heterogeneous, containing multiple cell types, and thus may have masked CCV effects
on DUSP4 expression that occur in specific cell types; and (iii) CCVs could have development or
context-specific effects on DUSP4 expression that were not captured by the available studies.
DUSP4 encodes a nuclear dual specificity protein phosphatase that inactivates ERK, JNK, and
p38 mitogen-activated protein kinases [18] and may also play a regulatory role in gene expression
through chromatin binding [19]. DUSP4 is frequently deleted in breast tumours [20,21] and cancer cell
lines [22]. DUSP4 knockdown enhances the formation of breast cancer stem cells [19,23] and increases
the invasive ability of estrogen receptor-positive breast cancer stem cells [23]. In ER-negative breast
cancer cells, DUSP4 knockdown increases the formation of mammospheres and the expression of
cancer stem cell promoting cytokines [22]. Thus, the literature indicates that DUSP4 protein acts as a
tumour suppressor in breast cancer, which is compatible with our finding of its negative regulation by
a breast cancer risk allele.
4. Materials and Methods
4.1. Cell Culture
MCF-7 and T-47D cell lines were purchased from ATCC (#HTB22 and #HTB-133, respectively),
and Bre-80 was kindly provided by Roger Reddel (CMRI, Sydney, Australia). Cell lines were stored in
liquid nitrogen vapour phase with Mycoplasma testing and short tandem repeat profiling performed
for cell authentication prior to storage. The immortalised mammary epithelial Bre-80 cell line was
cultured as previously described [24]. The breast cancer cell lines MCF-7 and T-47D were cultured in
RPMI 1640 medium supplemented with fetal calf serum, penicillin/streptomycin, and 10 µg/ml insulin.
All cell lines were cultured at 37 ◦C in a humidified 5% CO2 atmosphere.
4.2. C Analysis
3C libraries were generated from MCF-7, T-47D, and Bre-80 cells. Briefly, cells were grown in
100 mm plates and fixed with 1% formaldehyde after reaching ≈80% confluency. Formaldehyde was
quenched with ice-cold 0.125 M glycine in phosphate buffered saline and cells collected by scraping
and centrifugation. After washing with PBS, cells were incubated in ice-cold cell lysis buffer (10 mM
Tris pH 7.5, 10 mM NaCl, 0.2% IGEPAL and cOmplete protease inhibitors (Roche)) for 30 min on ice,
followed by 10 strokes of a Dounce homogenizer. Cell nuclei were collected by centrifugation and
incubated overnight at 37 ◦C with 1500 U of EcoRI in New England Biolabs restriction buffer with 0.3%
sodium dodecyl sulfate and 2% Triton-X 100. Restriction enzyme was heat-inactivated at 65 ◦C for
20 min and ligation was performed in 8 mL of ligation buffer (1% Triton X-100, 1.15× NEB ligation
buffer, 0.1 mg/mL bovine serum albumin and 1 mM ATP). 3C libraries were then phenol/chloroform
extracted and precipitated with ethanol.
3C interactions were quantified by qPCR with primers designed with the EcoRI restriction
fragments spanning the 8p12 risk locus (Supplementary Table S2). qPCR was performed using a
RotorGene 6000 with a reaction mix containing MyTaq HS DNA polymerase and the addition of 5 mM
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Syto9. Thermal cycling was performed with an annealing temperature of 66 ◦C (20 s) and extension at
72 ◦C (30 s). Three independent 3C libraries were analysed by qPCR with each experiment quantified
in duplicate. Two bacterial artificial clones (RP11-56L5 and RP11-833O14: BACPAC Resource Center)
encompassing the DUSP4 promoter region and the 8p12 breast cancer risk locus were used to create a
library of ligation products to determine 3C primer efficiencies for normalization.
4.3. Reporter Gene Vector Construction
A DUSP4 promoter luciferase reporter construct was generated by inserting 1650 bp of
PCR-amplified DNA, containing the DUSP4 transcription start site (chr8:29,207,878-29,209,527;
GRCh37), into the KpnI and HindIII sites of a pGL3-Basic construct. The pGL3-Basic construct had been
engineered to include AgeI and SbfI sites downstream of the luciferase gene. A 2464 bp PRE1 region
(chr88:29,527,323-29,530,033) was PCR generated using primers engineered with BamHI and SalI sites
for insertion downstream of the Firefly luciferase gene. A 980 bp PRE2 region (chr8:29522728-29523707)
was synthesised with terminal AgeI/SalI sites (Integrated DNA Technologies, Singapore, Singapore)
for cloning into the DUSP4 promoter construct. For PRE1, the allelic variants of CCVs were introduced
by overlap extension PCR. For PRE2, constructs containing allelic variants were also synthesised by
Integrated DNA Technologies and cloned as above. All constructs were Sanger sequenced (QIMR
Berghofer sequencing facility) to confirm variant incorporation. All PCR and sequencing primers are
listed in Supplementary Table S3.
4.4. Reporter Gene Analysis
Bre-80, MCF-7, and T-47D cells were transfected with equimolar amounts of luciferase reporter
constructs and 50 ng of the Renilla luciferase pRL-SV40 construct with Lipofectamine 2000. The total
amount of transfected DNA was kept constant at 600 ng for each construct by adding pUC19 as a
carrier plasmid. Luciferase activity was measured 24 h post-transfection by the Dual-Glo Luciferase
Assay System. To correct for variation in transfection efficiency or cell lysate preparation, Firefly
luciferase activity was normalised to that of the Renilla luciferase. All DUSP4 promoter constructs
had great activity compared with the negative control (empty pGL3-Basic construct). Data were
log-transformed and statistical significance was assessed by two-way ANOVA, followed by Dunnett’s
multiple comparisons test in GraphPad Prism (version 7.02, GraphPad Software, San Diego, CA, USA).
4.5. Allele-Specific 3C Analysis
DNA was amplified by PCR of two independent Bre-80 3C libraries using the DUSP4 promoter
bait primer and a reverse primer specific to the PRE2 fragment containing rs12155535 (Supplementary
Table S2). The region containing rs12155535 was also amplified from Bre-80 genomic DNA as a control.
Sanger sequencing (QIMR Berghofer sequencing facility) was performed to determine the alleles
present in the interacting PRE2 fragment.
5. Conclusions
We found the first evidence that breast cancer risk variation at the 8p12 locus downregulates
DUSP4 promoter activity and is negatively correlated with long-range chromatin looping interactions
with the DUSP4 promoter region. These findings are consistent with the role of DUSP4 as a tumour
suppressor in breast cancer and suggest that the effects of CCVs on breast cancer risk may be mediated
by a reduction in DUSP4 expression.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/1/170/s1.
Figure S1: Luciferase reporter gene analysis of PRE1-3 in T-47D cells, Table S1: 8p12 CCVs, Table S2: 3C primers,
Table S3: Primers for generation of reporter gene constructs.
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